EP2252300
Notkun á 2,4-pýrimídíndíamínum við meðhöndlun á æðakölkun
Status:
EP Einkaleyfi fallið úr gildiEP appl. date:
20.2.2009EP published:
19.10.2016EP application number:
09711944.0
EP translation filed:
16.1.2017Grant published:
15.2.2017EPO information:
European Patent Register
Max expiry date:
19.2.2029Expiry date:
19.2.2024
Title:
USE OF 2,4-PYRIMIDINEDIAMINES FOR THE TREATMENT OF ATHEROSCLEROSIS
Timeline
Today
20.2.2009EP application
19.10.2016EP Publication
16.1.2017Translation submitted
15.2.2017Registration published
19.2.2024Expires
Owner
Name:
Rigel Pharmaceuticals, Inc.Address:
1180 Veterans Boulevard, 94080, South San Francisco, CA, US
Inventor
Name:
MASUDA, EstebanAddress:
Menlo ParkCalifornia, US
Name:
SCHMITZ, JochenAddress:
Indianapolis, Indiana, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
30903Date:
22.2.2008Country:
US
Classification
Categories:
A61K 31/5383, A61K 31/662, A61P 9/10
Annual fees
Number
Paid
Expires
Payer
Number: 9
Paid: 31.1.2017
Expires: 19.2.2018
Payer: Sigurjónsson & Thor ehf.
Number: 10
Paid: 31.1.2018
Expires: 19.2.2019
Payer: Sigurjónsson & Thor ehf.
Number: 11
Paid: 31.1.2019
Expires: 19.2.2020
Payer: Sigurjónsson & Thor ehf.
Number: 12
Paid: 26.2.2020
Expires: 19.2.2021
Payer: Sigurjónsson & Thor ehf.
Number: 13
Paid: 2.2.2021
Expires: 19.2.2022
Payer: Sigurjónsson & Thor ehf.
Number: 14
Paid: 1.2.2022
Expires: 19.2.2023
Payer: Patice ehf.
Number: 15
Paid: 31.1.2023
Expires: 19.2.2024
Payer: Árnason Faktor ehf.
Number: 15
Paid: 31.1.2023
Expires: 19.2.2024
Payer: Árnason Faktor ehf.